Navigation Links
Champions Oncology, Inc. Appoints Executive Vice President and Chief Financial Officer to Management Team and Corporate Office Relocation
Date:11/1/2011

HACKENSACK, N.J., Nov. 1, 2011 /PRNewswire/ -- Champions Oncology, Inc.  ("Champions" or  the "Company") (OTC Bulletin Board: CSBR) , a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, has appointed Gary G. Gemignani to the Company's management team, as Executive Vice President and Chief Financial Officer. Joel Ackerman, the Company's Chief Executive Officer, served as interim Chief Financial Officer, until Mr. Gemignani's appointment. Mr. Ackerman commented, "We are pleased to add an executive with Gary's background and vast experiences as we continue to build our management team."

Most recently, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Coronado Biosciences, a company focused on novel immunotherapy agents for cancer and inflammatory diseases. From June 2005 through March 2010, Mr. Gemignani served as Executive Vice President, Chief Operating Officer and Chief Financial Officer for Gentium S.p.A., a biotechnology company focused on developing products to address complications of cancer therapy. Prior to that Mr. Gemignani held management positions of increasing responsibility at Wyeth, Novartis and Prudential Financial. Mr. Gemignani received a Bachelor's Degree in Accounting from St. Peter's College.

Additionally, Champions announces the relocation of its corporate office from Baltimore, MD to Hackensack, NJ.

About Champions Oncology, Inc.

Champions Oncology, Inc. (formerly Champions Biotechnology, Inc.) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company's Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. The Company uses this technology in conjunction with related services to offer solutions for two customer groups:  Personalized Oncology Solutions ("POS") in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions ("TOS") in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company's Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. The Company is building its Tumorgraft™ Technology Platform through the procurement, development and characterization of numerous Tumorgrafts™ within each of several cancer types. Tumorgrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business. The Tumorgrafts™ are developed and tested through agreement with a United States-based preclinical facility.

The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate. Additionally, the Company offers Personalized Tumorgraft™ development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients' Tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

Media Contact:
Susan Foreman
410-369-0365
sforeman@championsoncology.com


'/>"/>
SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
2. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
3. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
4. Champions CFO Resigns
5. Champions Biotechnology Awarded $1.46 million in Grants
6. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
7. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
10. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Research and Markets has announced the addition of ... Infrared, Mercury; Trend Indicator):Analysis By Region, By Country (2016-21)" report ... ... at a CAGR of 5.33% during 2016-2021 The strong ... with surging demand of digital thermometer. Apart from that, the downfall ...
(Date:2/22/2017)... 2017 Oncternal Therapeutics, Inc., a clinical-stage ... and common malignancies, today announced the closing of ... intends to use the proceeds to further clinical ... advance preclinical development of a new ROR1-targeted antibody-drug ... first-in-class anti-ROR1 monoclonal antibody being developed to treat ...
(Date:2/22/2017)... 22, 2017 Kineta, Inc., a biotechnology ... immune modulating therapies, today announced that KCP-400 (RgIA4), ... receptor (nAChR), demonstrates robust chronic pain relief and ... study also establishes the a9a10 nAChR as a ... pain. The findings were reported online in the ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a ... innovation in the delivery of Platelet Rich Plasma (PRP). PRP systems are used ... to accelerate tissue synthesis and provide a faster and more efficient healing process. ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... suffer from combat-related PTSD. , Established in 1977, our organization was at the ... of military returning to civilian life were evident and served as the catalyst ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & ... in Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon ... clinic employees, the construction team and tribal leadership. , Choctaw Nation Durant ...
Breaking Medicine News(10 mins):